Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic faecal microbiota
- Development stage
- Unknown
- Lead developer
- MaaT Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Allogeneic faecal microbiota is a microbial therapy consisting of a diverse community of microorganisms derived from the stool of a healthy donor. Developed by the University Hospital of Clermont-Ferrand for the treatment of hidradenitis suppurativa (HS), the therapy is based on the hypothesis that gut dysbiosis contributes to the systemic inflammation characteristic of HS. By transplanting a healthy microbiome, the treatment aims to restore intestinal homeostasis, modulate the gut-skin axis, and ultimately reduce the inflammatory load and severity of skin lesions. It is typically administered via colonoscopy, enema, or oral capsules.
- Other names
- Fecal microbiota transplantFMTallogeneic fecal microbiota transplantation
02
Targets
CLR (C-type lectin receptors)TLR (Toll-like receptors)NLRP6 inflammasomeBARs (Bile acid receptors)AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on allogeneic faecal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic faecal microbiota.